Outcomes analysis in HER2-low gastric cancer using multimodal RWD
RWD analysis reveals a poor prognosis for HER2-low gastric cancer patients
Figure 1: Median OS (mOS, months) was 9.8 (9.1, 12.8) for HER2-low, 10.8 (8.2, 17.4) for HER2(-), and 14.2 (12.2,19.9) for HER2(+). Figure 2: For RNA expression analysis, the mOS was 9.8 (8.8, 13.8) months for HER2-low, 10.9 (6.9, 15.7) months for HER2(-), and 12.4 (10.2, 16.6) months for HER2(+).
Lens Library
